Prot #CAIN457AUS01: A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the efficacy of subcutaneous secukinumab [300 mg] as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of treatment, compa

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date11/5/146/30/16

    Funding

    • Novartis Pharmaceuticals Corporation (Prot #CAIN457AUS01)